Polyenylphosphatidylcholines as bioactive excipient in tablets for the treatment of liver fibrosis.

Skorup, Ivo; Valentino, Gina; Aleandri, Simone; Gelli, Rita; Ganguin, Aymar Abel; Felli, Eric; Selicean, Sonia Emilia; Marxer, Rosanne Angela; Teworte, Sarah; Lucić, Ana; Gracia-Sancho, Jordi; Berzigotti, Annalisa; Ridi, Francesca; Luciani, Paola (2023). Polyenylphosphatidylcholines as bioactive excipient in tablets for the treatment of liver fibrosis. International journal of pharmaceutics, 646, p. 123473. Elsevier 10.1016/j.ijpharm.2023.123473

[img]
Preview
Text
1-s2.0-S0378517323008943-main.pdf - Accepted Version
Available under License Creative Commons: Attribution (CC-BY).

Download (3MB) | Preview

Liver fibrosis is a condition characterized by the accumulation of extracellular matrix (ECM) arising from the myofibroblastic transdifferentiation of hepatic stellate cells (HSCs) occurring as the natural response to liver damage. To date, no pharmacological treatments have been specifically approved for liver fibrosis. We recently reported a beneficial effect of polyenylphosphatidylcholines (PPCs)-rich formulations in reverting fibrogenic features of HSCs. However, unsaturated phospholipids' properties pose a constant challenge to the development of tablets as preferred patient-centric dosage form. Profiting from the advantageous physical properties of the PPCs-rich Soluthin® S 80 M, we developed a tablet formulation incorporating 70% w/w of this bioactive lipid. Tablets were characterized via X-ray powder diffraction, thermogravimetry, and Raman confocal imaging, and passed the major compendial requirements. To mimic physiological absorption after oral intake, phospholipids extracted from tablets were reconstituted as protein-free chylomicron (PFC)-like emulsions and tested on the fibrogenic human HSC line LX-2 and on primary cirrhotic rat hepatic stellate cells (PRHSC). Lipids extracted from tablets and reconstituted in buffer or as PFC-like emulsions exerted the same antifibrotic effect on both activated LX-2 and PRHSCs as observed with plain S 80 M liposomes, showing that the manufacturing process did not interfere with the bioactivity of PPCs.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
08 Faculty of Science > Department of Chemistry, Biochemistry and Pharmaceutical Sciences (DCBP)
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Skorup, Ivo, Valentino, Gina, Aleandri, Simone, Ganguin, Aymar Abel, Felli, Eric, Selicean, Sonia-Emilia, Teworte, Sarah, Gracia Sancho, Jorge Sergio, Berzigotti, Annalisa, Luciani, Paola

Subjects:

500 Science > 570 Life sciences; biology
500 Science > 540 Chemistry
600 Technology > 610 Medicine & health

ISSN:

1873-3476

Publisher:

Elsevier

Language:

English

Submitter:

Pubmed Import

Date Deposited:

04 Oct 2023 12:24

Last Modified:

25 Oct 2023 00:16

Publisher DOI:

10.1016/j.ijpharm.2023.123473

PubMed ID:

37788730

Uncontrolled Keywords:

hepatic stellate cells lipid-based tablets liver fibrosis phospholipids

BORIS DOI:

10.48350/186889

URI:

https://boris.unibe.ch/id/eprint/186889

Actions (login required)

Edit item Edit item
Provide Feedback